Inert Gas Rebreathing in Ventilated Patients

NCT ID: NCT01891253

Last Updated: 2019-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Measuring hemodynamic parameters in ventilated patients is important yet still complicated to perform. Inert gas rebreathing (IGR) showed promising results when being compared to other invasive as well as non-invasive techniques for the measurement of cardiac output. The aim of our study is to evaluate the feasibility of IGR in ventilated patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Respiratory Failure Heart Failure Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ventilated patients

ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring

non-invasive determination of cardiac output

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

non-invasive determination of cardiac output

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18 - 80 years
* mechanically ventilated patient
* existing PiCCO arterial line

Exclusion Criteria

* FiO2 \> 60% (fraction of inspired oxygen)
* PEEP \> 10 mmHg (positive end-expiratory pressure)
* SO2 \< 90% (oxygen saturation )
* Systolic blood pressure \< 90 mmHg
* Heart rate \> 150 bpm
* APRV (airway pressure release ventilation)
* ICD (implantable cardioverter defibrillator) / pace maker
* \[ Anaesthetic Conserving Device (Anaconda) \]
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitätsmedizin Mannheim

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Joachim Saur

Priv.-Doz. Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joachim Saur, MD

Role: PRINCIPAL_INVESTIGATOR

Universitätsmedizin Mannheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universitätsmedizin Mannheim

Manheim, Baden-Wurttemberg, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VIGR_MA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.